You are here: Home » News-CM » Companies » News
Business Standard

USFDA refuses admission to drugs manufactured by Ipca Laboratories

Capital Market 

At its units in Indore (Pithampur) and Piparia (Silvassa)

announced that it has received a communication from USFDA stating that all the drugs manufactured from the Company's manufacturing units situated at Indore (Pithampur) and Piparia (Silvassa) will be henceforth refused admission into the United States until the Company can demonstrate that the drugs manufactured sites and intended for the US market are in compliance with cGMP.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)